Description: <p><b>Astragalus</b> — Astragalus (AG; typically <i>Astragalus membranaceus</i> root, “Huangqi”) is a traditional botanical immunomodulator composed of multiple bioactive fractions, notably astragaloside IV (AS-IV; triterpenoid saponin), Astragalus polysaccharides (APS; high–molecular-weight glycans), and flavonoids. It is best classified as a multi-constituent herbal drug (botanical) whose dominant functional identity is immune regulation with secondary inflammation- and stress-response tuning. Common abbreviations include AG, AS-IV, and APS. In oncology contexts it is most often positioned as adjunct/supportive care rather than a validated standalone anticancer agent.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Immune modulation with enhanced innate/adaptive effector function (macrophage, NK, T-cell activity; context-dependent antitumor immunity)</li>
<li>Checkpoint and tumor–immune interface modulation (e.g., PD-L1 downregulation reported for APS in some models)</li>
<li>Inflammation pathway tuning (NF-κB and cytokine networks; bidirectional depending on immune context)</li>
<li>Growth/survival signaling modulation (PI3K/Akt/mTOR and MAPK; model- and constituent-dependent)</li>
<li>EMT/migration programs (Wnt/β-catenin axis suppression reported in some tumor models)</li>
<li>Redox/stress-response effects (ROS buffering and NRF2 activation are commonly reported; may be protective rather than directly cytotoxic)</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Constituent-dependent. AS-IV has low oral bioavailability and limited systemic exposure in typical oral-use scenarios; APS are poorly absorbed and are more plausibly active via gut–immune signaling and downstream immunomodulation rather than direct tumor exposure. Extract variability (species, processing, standardization) is a major translational confounder.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic cancer studies use purified AS-IV or APS at concentrations unlikely to reflect achievable human plasma levels from typical oral extracts; immune-mediated and gut–immune mechanisms are often more plausible clinically than direct concentration-driven tumor cell cytotoxicity.</p>
<p><b>Clinical evidence status:</b> Human evidence is strongest for adjunctive use alongside standard therapy (quality-of-life, fatigue, immune parameters, and some meta-analyses reporting improved response/toxicity profiles in specific settings). Robust evidence for standalone anticancer efficacy is not established.</p>
<a href="https://www.healthline.com/nutrition/astragalus"> <b>Astragalus</b></a> is an herb that has been used in traditional Chinese medicine for centuries.It has many purported health benefits, including immune-boosting, anti-aging and anti-inflammatory effects. <br>
Astragalus (AG; commonly referring to Astragalus membranaceus root; major constituents: astragaloside IV [AS-IV], polysaccharides [APS], flavonoids) is a traditional botanical immunomodulator. Its dominant biology is immune modulation and stress-adaptive signaling, ranking conceptually as: <br>
(1) immune activation/regulation (macrophage, NK, T-cell modulation), <br>
(2) NF-κB and inflammatory pathway tuning, <br>
(3) PI3K/Akt/mTOR and MAPK context-dependent signaling, and <br>
(4) NRF2-mediated cytoprotection/antioxidant effects. <br>
Bioavailability is variable and constituent-dependent; AS-IV has relatively low oral bioavailability, APS are high-molecular-weight and act largely via gut–immune interaction. Many in-vitro cancer studies use purified compounds at concentrations exceeding typical plasma levels. Clinical evidence exists primarily as adjunctive oncology support (quality-of-life, immune parameters); robust standalone anticancer efficacy is not established. Immune stimulation may enhance antitumor surveillance but effects are tumor- and context-dependent.<br>
<br>
<h3>Astragalus (AG) — Cancer-Relevant Pathway Effects</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Immune Activation</td>
<td>↑ immune-mediated cytotoxicity (context-dependent)</td>
<td>↑ immune competence</td>
<td>G</td>
<td>Immunomodulation</td>
<td>APS frequently show macrophage/NK/T-cell modulation in preclinical systems; clinical positioning is commonly adjunctive/supportive.</td>
</tr>
<tr>
<td>2</td>
<td>PD-1 / PD-L1 Axis</td>
<td>↓ PD-L1 (model-dependent); ↑ antitumor immunity</td>
<td>↔</td>
<td>R–G</td>
<td>Immune checkpoint interface</td>
<td>APS has been reported to reduce PD-L1–mediated immunosuppression in some tumor models; translation to clinical checkpoint therapy remains uncertain.</td>
</tr>
<tr>
<td>3</td>
<td>NF-κB Signaling</td>
<td>↓ NF-κB (tumor-promoting inflammation; context-dependent)</td>
<td>↔ / balanced activation</td>
<td>R–G</td>
<td>Inflammatory pathway tuning</td>
<td>Commonly described as anti-inflammatory in many models, but immune-activation contexts can require transient inflammatory signaling.</td>
</tr>
<tr>
<td>4</td>
<td>PI3K/Akt/mTOR</td>
<td>↓ Akt/mTOR signaling (model-dependent)</td>
<td>↔ / survival support (context-dependent)</td>
<td>R–G</td>
<td>Anti-proliferative signaling</td>
<td>Often demonstrated with purified constituents and/or higher in-vitro concentrations; may contribute to growth suppression in select models.</td>
</tr>
<tr>
<td>5</td>
<td>MAPK Axis</td>
<td>↓ ERK; ↑ JNK/p38 (stress/apoptosis; model-dependent)</td>
<td>↔ adaptive stress response</td>
<td>R</td>
<td>Stress-response reshaping</td>
<td>Directionality varies by fraction (AS-IV vs APS vs flavonoids), tumor type, and dose.</td>
</tr>
<tr>
<td>6</td>
<td>Wnt / β-catenin and EMT</td>
<td>↓ Wnt/β-catenin; ↓ EMT; ↓ migration/invasion (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Anti-metastatic phenotype shift</td>
<td>Reported in several preclinical models; relevance depends on whether adequate exposure and target engagement occur in vivo.</td>
</tr>
<tr>
<td>7</td>
<td>Glycolysis and HIF-1α</td>
<td>↓ glycolysis / ↓ lactate (model-dependent)</td>
<td>↔</td>
<td>R–G</td>
<td>Metabolic downshift</td>
<td>Metabolic effects are described in some models, but may be secondary to upstream signaling and inflammatory-state changes.</td>
</tr>
<tr>
<td>8</td>
<td>Angiogenesis</td>
<td>↓ pro-angiogenic signaling (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Anti-angiogenic tendency</td>
<td>Evidence is preclinical and heterogeneous; may be indirect via NF-κB/cytokine modulation.</td>
</tr>
<tr>
<td>9</td>
<td>ROS Modulation</td>
<td>↓ ROS (dose-dependent)</td>
<td>↓ ROS (protective)</td>
<td>P–R</td>
<td>Redox buffering</td>
<td>Can be supportive for normal-tissue protection; may be counterproductive if combined with therapies relying on oxidative cytotoxicity (context-dependent).</td>
</tr>
<tr>
<td>10</td>
<td>NRF2 Axis</td>
<td>↑ NRF2 (context-dependent)</td>
<td>↑ NRF2 (cytoprotection)</td>
<td>R–G</td>
<td>Antioxidant gene induction</td>
<td>NRF2 activation can protect normal tissues but may also support tumor stress tolerance in some contexts; mechanistic centrality varies by fraction.</td>
</tr>
<tr>
<td>11</td>
<td>Chemosensitization</td>
<td>↑ chemo-sensitization reported (model-dependent)</td>
<td>↑ tolerance to toxicity (context-dependent)</td>
<td>G</td>
<td>Adjunct compatibility</td>
<td>Clinical literature is mixed and highly formulation-specific; some meta-analyses suggest improved tolerance and response when combined with standard regimens in selected settings.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td colspan="2">Constituent variability; low AS-IV oral exposure; APS primarily gut–immune; in-vitro dosing often non-physiologic; interaction risk with immunosuppressants/anticoagulants</td>
<td>—</td>
<td>Heterogeneity / PK</td>
<td>Most credible clinical role is adjunct/supportive care with careful attention to product standardization and drug–herb interaction risk.</td>
</tr>
</table>
<div><b>TSF Legend:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</div>
<br>
<br>
<p><b>Astragalus</b> — In Alzheimer’s disease (AD) and broader neurodegeneration models, Astragalus fractions (notably AS-IV and flavonoids; sometimes APS indirectly) are most often described as cytoprotective via anti-inflammatory and antioxidant programs, with secondary support of pro-survival signaling and mitochondrial stability. Evidence is primarily preclinical; high-quality AD RCT efficacy remains unestablished.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Oxidative stress reduction and cellular stress buffering (context-dependent)</li>
<li>Neuroinflammation suppression (microglial and NF-κB-linked cytokine modulation)</li>
<li>Pro-survival signaling support (e.g., PI3K/Akt in injury/neurodegeneration models; context-dependent)</li>
<li>Mitochondrial stabilization and metabolic support (model-dependent)</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> AS-IV systemic exposure is limited with typical oral dosing; CNS relevance depends on formulation and model. Many findings use purified compounds and dosing not directly comparable to common supplement use.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Numerous neuronal studies employ concentrations/doses that may exceed achievable CNS exposure; interpretation should emphasize direction-of-effect rather than assuming clinical target engagement.</p>
<p><b>Clinical evidence status:</b> Predominantly preclinical; insufficient robust AD-specific RCT evidence for disease-modifying benefit.</p>
<h3>Astragalus (AG) — Alzheimer’s Disease (AD)-Relevant Effects</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>AD Context</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes</th>
</tr>
<tr>
<td>1</td>
<td>Oxidative Stress</td>
<td>↓ neuronal ROS (context-dependent)</td>
<td>P–R</td>
<td>Neuroprotection</td>
<td>Often attributed to flavonoids/AS-IV in model systems; translation depends on exposure and disease stage.</td>
</tr>
<tr>
<td>2</td>
<td>Neuroinflammation</td>
<td>↓ microglial activation; ↓ inflammatory cytokines (model-dependent)</td>
<td>R–G</td>
<td>Anti-inflammatory</td>
<td>Commonly framed through NF-κB-linked pathways in preclinical literature.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K/Akt Survival Pathway</td>
<td>↑ neuronal survival signaling (context-dependent)</td>
<td>G</td>
<td>Pro-survival support</td>
<td>Often studied in ischemia/toxicity paradigms rather than human AD pathology directly.</td>
</tr>
<tr>
<td>4</td>
<td>Mitochondrial Function</td>
<td>↑ mitochondrial stability (model-dependent)</td>
<td>R–G</td>
<td>Energy support</td>
<td>Reported improvements in mitochondrial dynamics/oxidative injury markers in some models.</td>
</tr>
<tr>
<td>5</td>
<td>Clinical Translation Constraint</td>
<td>No robust AD RCT efficacy data</td>
<td>—</td>
<td>Evidence gap</td>
<td>Current evidence is insufficient to claim disease-modifying clinical benefit in AD.</td>
</tr>
</table>
<div><b>TSF Legend:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</div>